Clinical prognostic value of circulating tumor cells in the treatment of pancreatic cancer with gemcitabine chemotherapy

Wang, Xiaoguang; Hu, Lingyu; Yang, Xiaodan; Chen, Fei; Xu, Haokai; Yu, Haitao; Song, Zhengwei; Fei, Jianguo; Zhong, Zhengxiang

doi:10.3892/etm.2021.10574

Cited by 3 publications

(1 citation statement)

References 39 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early diagnosis [39] HOTAIR MALAT-1 Prognosis [40] LINC00460 Prognosis [41] PVT1 Monitoring treatment response [42] Circulating tumour cells Diagnosis [43] Prognosis [44] Vimentin (surface marker) Monitoring treatment response [45] Monitoring tumour recurrence [46] Metabolites Panel of acetylspermidine, diacetylspermine, indole-derivative and two lysophosphatidylcholines…”

Section: Snhg15mentioning

confidence: 99%

Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review

Vellan

Jayapalan

Yoong

et al. 2022

IJMS

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC), a highly aggressive malignancy with a poor prognosis is usually detected at the advanced stage of the disease. The only US Food and Drug Administration-approved biomarker that is available for PDAC, CA 19-9, is most useful in monitoring treatment response among PDAC patients rather than for early detection. Moreover, when CA 19-9 is solely used for diagnostic purposes, it has only a recorded sensitivity of 79% and specificity of 82% in symptomatic individuals. Therefore, there is an urgent need to identify reliable biomarkers for diagnosis (specifically for the early diagnosis), ascertain prognosis as well as to monitor treatment response and tumour recurrence of PDAC. In recent years, proteomic technologies are growing exponentially at an accelerated rate for a wide range of applications in cancer research. In this review, we discussed the current status of biomarker research for PDAC using various proteomic technologies. This review will explore the potential perspective for understanding and identifying the unique alterations in protein expressions that could prove beneficial in discovering new robust biomarkers to detect PDAC at an early stage, ascertain prognosis of patients with the disease in addition to monitoring treatment response and tumour recurrence of patients.

show abstract

Section: Snhg15mentioning

confidence: 99%

Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review

Vellan

Jayapalan

Yoong

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

The Value of Circulating Tumor Cells in the Prognosis and Treatment of Pancreatic Cancer

et al. 2022

View full text Add to dashboard Cite

In the past few decades, tumor diagnosis and treatment theory have developed in a variety of directions. The number of people dying from pancreatic cancer increases while the mortality rate of other common tumors decreases. Traditional imaging methods show the boundaries of pancreatic tumor, but they are not sufficient to judge early micrometastasis. Although carcinoembryonic antigen (CEA) and carbohydrate antigen19-9 (CA19-9) have the obvious advantages of simplicity and minimal invasiveness, these biomarkers obviously lack sensitivity and specificity. Circulating tumor cells (CTCs) have attracted attention as a non-invasive, dynamic, and real-time liquid biopsy technique for analyzing tumor characteristics. With the continuous development of new CTCs enrichment technologies, substantial progress has been made in the basic research of CTCs clinical application prospects. In many metastatic cancers, CTCs have been studied as an independent prognostic factor. This article reviews the research progress of CTCs in the treatment and prognosis of pancreatic cancer.

show abstract

Circulating tumor cells as prognostic marker in pancreatic cancer

Yakar,

Etiz

2024

World J Clin Oncol

View full text Add to dashboard Cite

In this editorial we comment on the article by Zhang et al published in the recent issue of the World Journal of Clinical Oncology . Pancreatic cancer is the fourth most common cause of cancer-related mortality and has the lowest survival rate among all solid cancers. It causes 227000 deaths annually worldwide, and the 5-year survival rate is very low due to early metastasis, which is 4.6%. Cancer survival increases with better knowledge of risk factors and early and accurate diagnosis. Circulating tumor cells (CTCs) are tumor cells that intravasate from the primary tumor or metastasis foci into the peripheral blood circulation system spontaneously or during surgical operations. Detection of CTC in blood is promising for early diagnosis. In addition, studies have associated high CTC levels with a more advanced stage, and more intensive treatments should be considered in cases with high CTC. In tumors that are considered radiologically resectable, it may be of critical importance in detecting occult metastases and preventing unnecessary surgeries.

show abstract

Clinical prognostic value of circulating tumor cells in the treatment of pancreatic cancer with gemcitabine chemotherapy

Cited by 3 publications

References 39 publications

Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review

Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review

The Value of Circulating Tumor Cells in the Prognosis and Treatment of Pancreatic Cancer

Circulating tumor cells as prognostic marker in pancreatic cancer

Contact Info

Product

Resources

About